Grant✓ Small businesses may apply
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
$150,000
Program funding
$5,100,000
- Opportunity #
- RFA-CA-27-001
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.394
- Status
- posted
- Posted
- Jun 3, 2026
- Closes
- Nov 10, 2026
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Independent school districts
- •State governments
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Native American tribal governments (Federally recognized)
- •County governments
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •For profit organizations other than small businesses
- •Small businesses
- •Public and State controlled institutions of higher education
- •Special district governments
- •Public housing authorities/Indian housing authorities
- •City or township governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Private institutions of higher education
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Contact
National Institutes of Health · Kelly.crotty@nih.gov